undamentalytics Newsletter
Sign in

Tarsus Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Tarsus Pharmaceuticals, Inc.'s operations generated −$12.5m of cash; it spent $9.9m on capital projects, leaving free cash flow of −$22.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−214−49−117−83−1274
Depreciation and amortisation0001111
Stock-based pay181320284252
Capital spending011221018
Free cash flow−223−50−119−85−2256
Free cash flow after stock pay−22−5−63−139−112−644

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MIRM vs TARSARWR vs TARSHCM vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tarsus Pharmaceuticals, Inc.